No image available for this title

LITERATURE

Alemtuzumab to Treat Refractory Autoimmune Hemolytic Anemia or Thrombocytopenia in Chronic Lymphocytic Leukemia


Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP) are recognized complications of chronic lymphocytic leukemia (CLL) that can be life-threatening if not managed appropriately. Conventional therapies for these autoimmune disorders, such as corticosteroids, splenectomy, and immunosuppressive agents, may not induce complete
resolution in all patients, and relapses are common. In recent years, monoclonal antibodies such as alemtuzumab
and rituximab, already used successfully for the management of lymphoproliferative disorders, have been shown to be effective in the treatment of a range of autoimmune disorders.


Availability

REQJ740-1Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Current Hematologic Malignancy Reports 2009, 4:47–53
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous